ABBV-181 for HIV

"Presently, there are 6 running studies for the ABBV-181 drug with none of them in their concluding phase. The majority of these trials take place in Hamburg and Lazio, but research is being done at 178 medical centres worldwide."

"Presently, 6 trials related to ABBV-181 are taking place in 81 cities and 13 countries. In 2018, AbbVie sponsored the initial trial of this drug which had 233 participants and concluded its Phase 1 stage with success. Since then, 18330 research studies have been accomplished."

"Unfortunately, no more patients can be registered for this clinical trial as recruitment is now closed. It originally appeared on 1/30/2020 and was last updated on 9/19/2022. For those searching for other studies, 695 trials are open to people with antibody deficiency syndrome and 6 medical experiments have vacancies for ABBV-181 participants."

"To qualify for this trial, patients must fall within the age range of 18 and 65. There are separate clinical trials available to individuals younger than 18 (195) or older than 65 (503)."

"Our assessment of ABBV-181's safety received a rating of 1 as this is an early stage trial, indicating limited evidence for both efficacy and patient protection."

"At present, the trial is being conducted at 14 medical centres. These are situated in Miami Beach, Miami and Fort Pierce as well as other cities around the continental US. To reduce unnecessary travel costs, it's recommended that you choose a clinic close to your home should you decide to enrol."

"As of the last update on September 19th 2022, this trial is not recruiting participants. However, if you are interested in participating in a study related to antibody deficiency syndrome there are presently 695 trials open and 6 studies actively accepting enrolment for ABBV-181."

"This clinical experiment is recruiting 41 patients with an immunodeficiency disease aged 18 to 65. These participants must meet a set of criteria, including: BMI between 18.0 and 35 kg/m2., HIV-1 infection while receiving antiretroviral therapy (ART) for at least 12 months before screening., Plasma HIV-1 RNA below lower limit of quantification (LLOQ), CD4+ T cell count >= 500 cells/uL prior to screening and during the previous year, CD4+ T cell nadir of >= 200 cells/uL when exposed chronically., Willingness to temporarily suspend ART"